Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

NCT00365144 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

University of California, San Francisco